(Total Views: 302)
Posted On: 09/08/2018 2:30:36 PM
Post# of 72447
Celgene Corporation (CELG) CEO Mark Alles on Citi's 13th Annual Biotech Conference (Transcript)
Sep. 6, 2018 7:05 PM•CELG
Celgene Corporation (NASDAQ:CELG)
Citi's 13th Annual Biotech Conference Call
September 6, 2018 12:00 PM ET
Mark Alles
That that’s the most important part for our industry. Do you recover the legitimate R&D costs that for us now include, for example, the spectacular disappointment of GED-0301, where we bought it for $700 million upfront. We developed it until the point, where it failed in Phase III for Crohn’s. That’s at least $1.2 billion out the door at risk......
This was just recent due diligence I found and find it very ironic and intriguing that IPIX was invited to speak about Brilacidin ongoing medicinal capabilities in its treatment of Chron's and inflammatory bowel syndrome with Celgene being the sponsorship to the symposium in New York Medical Academy in this coming November.....coincidence or novel approach to maybe fascinating idea! ......my thoughts, tryz
Sep. 6, 2018 7:05 PM•CELG
Celgene Corporation (NASDAQ:CELG)
Citi's 13th Annual Biotech Conference Call
September 6, 2018 12:00 PM ET
Mark Alles
That that’s the most important part for our industry. Do you recover the legitimate R&D costs that for us now include, for example, the spectacular disappointment of GED-0301, where we bought it for $700 million upfront. We developed it until the point, where it failed in Phase III for Crohn’s. That’s at least $1.2 billion out the door at risk......
This was just recent due diligence I found and find it very ironic and intriguing that IPIX was invited to speak about Brilacidin ongoing medicinal capabilities in its treatment of Chron's and inflammatory bowel syndrome with Celgene being the sponsorship to the symposium in New York Medical Academy in this coming November.....coincidence or novel approach to maybe fascinating idea! ......my thoughts, tryz
(3)
(0)
